The radiotherapy service at Queen Elizabeth Hospital Birmingham (QEHB) is supported by teams of highly specialist professionals with extensive experience in delivering a range of complex cancer treatments for various tumour sites and diagnoses.
The private patient service is provided by a team of leading clinical oncologists who are experts in their field. We aim to provide fast access to treatment in a caring, clean and comfortable environment.
All our patients receive a personalised treatment plan following a comprehensive multidisciplinary review. This review will involve a team of cancer clinicians and specialists from all disciplines who will work together to consider the most appropriate treatment options for you.
Your personalised treatment plan will be developed by our dedicated planning team, checked by expert clinical scientists, prescribed by our highly experienced consultant oncologists and delivered by our specialist teams of radiographers.
Your treatment will be delivered by a team of highly skilled therapeutic radiographers who are experienced and knowledgeable of the pre-treatment and treatment delivery processes.
They deliver a high standard of care and are focused on ensuring patients are informed and supported throughout the treatment journey. The team will also answer questions regarding treatment and any associated side effects.
We have a large team of clinical scientists and clinical technologists that provide scientific and technical support for the highly sophisticated and complex treatments provided for private patients at Queen Elizabeth Hospital Birmingham (QEHB).
The team consists of experienced and skilled clinical scientists, dosimetrists and equipment technicians.
Each patient has an individualised treatment plan developed by our team of highly trained planning dosimetrists. Each plan is designed to ensure that any tumours can receive the radiation dose prescribed by the consultant while minimising the dose received by nearby healthy tissue and sensitive organs.
Clinical scientists are part of the planning team which provides complex plans for advanced treatments such as CyberKnife and stereotactic radiotherapy (SABR).
Alongside routine clinical planning, the team is also involved in multiple national and international clinical trials, plus the development and implementation of new radiotherapy techniques, such as SABR. This commitment to research is a high priority for bringing new techniques into clinical use, with the ultimate aim of improving patient outcomes.
Machine maintenance and comprehensive quality assurance programmes are vital to ensure a safe and reliable service and are undertaken by our large team of skilled engineers and physicists.
Caroline trained as a radiographer and worked clinically for over 10 years before moving into operational management. She is now able to combine skills from both of these roles to benefit of our patients.
Her aim is to ensure treatment runs smoothly for patients and their families while they receive the very best care and treatment. Caroline is always available to answer any questions or queries.
Sandra has worked in the health service for a number of years and is now based in the Mindelsohn Suite.
She provides all patients and visitors with a warm welcome and any support or guidance they may require.
Sandra is always on hand to help organise appointments and to ensure your treatment causes minimum disruption to your everyday life.
Dr Dan Ford has been a Consultant Clinical Oncologist since 2007 and is based at the Queen Elizabeth Hospital Birmingham (QEHB).
Dr Ford played a key role in the clinical and strategic direction for the Oncology service, making research a core activity at QEHB to ensure patients have access to the most up-to-date treatment and technology with the aim of improving patient outcomes.
Dr Paul Sanghera led on the clinical implementation of IMRT and CyberKnife radiosurgery at Queen Elizabeth Hospital Birmingham (QEHB).
Paul is committed to improving radiotherapy and offering the most advanced treatment available to all patients. Dr Sanghera is the clinical service lead for the radiotherapy service at QEHB.
Dr Sanghera is the clinical service lead for the radiotherapy service at QEHB.
Dr Good trained at the Royal Marsden Hospital in London, where he developed expertise in the use of intensity modulated radiotherapy (IMRT), image guided radiotherapy (IGRT), and stereotactic body radiotherapy (SBRT).
Dr Good has extensive experience in radiotherapy treatment for liver, head and neck cancers. He has a special interest in bowel cancer and in addition to radiotherapy, he also uses chemotherapy and targeted therapy to treat both localised and advanced cancer of the colon and rectum.
Research interests include how drug treatments and radiotherapy can be combined or sequenced to achieve the best outcomes.
Dr El-Modir qualified in 1993 from the University of Al Fateh in Libya. He became a fellow of the Royal College of Radiologists in 2002. Interests include the treatment of prostate cancer with radiotherapy, hormones and chemotherapy.
Dr Ghafoor pioneered the development of the four-dimensional and stereotactic lung radiotherapy service in the Midlands. He leads the lung SABR and thoracic CyberKnife regional MDT and has published widely in this field, in addition to presenting at international conferences.
Dr Ghafoor is actively involved in ongoing research and is the principle investigator for a number of national clinical trials. He is currently developing new techniques to improve lung cancer outcomes, including breath holding techniques and pulmonary rehabilitation with radiotherapy.
Dr Stevenson specialises in the treatment of lung and urological cancers with chemotherapy, hormonal therapy and radiotherapy. He has a special interest in four dimensional and stereotactic lung radiotherapy and has experience in delivering CyberKnife treatment to early stage lung cancer.
Dr Stevenson has published papers in peer reviewed journals and is the principal investigator for a number of nationals clinical trials.
Specialist interests of Dr Stevens include breast cancer treatment and radiotherapy for lymphoma and other haematological malignancies, including total body radiotherapy as part of conditioning ahead of bone marrow transplantation.
Dr Stevens headed the West Midlands training scheme for clinical oncology for seven years, playing an integral part in training and educating junior colleagues and continues to be a clinical and educational supervisor for her trainees.
Dr Fernando sits on several national steering committees and his areas of interest include breast and gynaelogical cancers. Dr Fernando is the author of numerous publications on breast and gynaecological cancers.
In 1996 Dr Fernando was awarded the Frank Ellis medal by the Royal College of Radiologists and the Glory of India award for clinical excellence in 2010.
Dr Geh has a national profile for his research in the treatment of gastrointestinal cancers and in 1998 won the British Oncological Association Young Investigator’s Award for a project he completed on chemo radiotherapy treatment of rectal cancers.
Dr Geh has been published extensively in medical literature and lectures regularly at national and international conferences. He is a member of the National Cancer Research Institute (NCRI) Upper GI Clinical Trials Group and is the lead oncologist for the Pan-Birmingham Cancer Network Lower GI site-specific group.
Dr Anwar has extensive experience in radiotherapy treatment in addition to chemotherapy, biological and hormone therapies. His specialist interests include breast cancer and all types of gynaecological cancers, especially ovarian cancer.
Dr Anwar is involved in a variety of international, national and local chemotherapy trials and is the principal investigator for a number of radiotherapy trials. He also served as the chair of the Pan Birmingham Network site specific group for gynaecological cancers for a number of years.
Dr Zarkar has significant experience in the treatment of urological malignancies including prostate cancer, bladder cancer and kidney cancer.
Dr Zarkar takes part in a number of clinical trials in oncology and is the principal or co-investigator for numerous trials. She has a particular interest in stereotactic radiotherapy (SABR) to extracranial oligometastatic disease and is the lead clinician at QEHB.